These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35749049)
1. Identifying the primary site of malignancy in carcinomatous serous effusions using immunocytochemistry. Kundu R; Parwaiz A; Gupta P; Rohilla M; Gupta N; Srinivasan R; Dey P Cytopathology; 2022 Nov; 33(6):678-687. PubMed ID: 35749049 [TBL] [Abstract][Full Text] [Related]
2. Cytomorphological profile of neoplastic effusions: an audit of 10 years with emphasis on uncommonly encountered malignancies. Gupta S; Sodhani P; Jain S J Cancer Res Ther; 2012; 8(4):602-9. PubMed ID: 23361282 [TBL] [Abstract][Full Text] [Related]
3. Serous effusions in malignant lymphomas: a review. Das DK Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559 [TBL] [Abstract][Full Text] [Related]
4. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center. Lobo C; Costa J; Petronilho S; Monteiro P; Leça L; Schmitt F Diagn Cytopathol; 2021 May; 49(5):596-605. PubMed ID: 32339444 [TBL] [Abstract][Full Text] [Related]
5. The application of immunocytochemistry to direct smears in the diagnosis of effusions. Knoepp SM; Placido J; Fields KL; Thomas D; Roh MH Diagn Cytopathol; 2013 May; 41(5):425-30. PubMed ID: 22549950 [TBL] [Abstract][Full Text] [Related]
6. Initial panel of immunocytochemical markers for identification of primary carcinoma site for effusions and peritoneal washings from women. Takano GHS; Amorim RF; Ferreira VM; Vianna LMS; de Castro TMML; Carneiro MV; Oliveira ÍA; Motoyama AB; Carneiro FP Int J Clin Exp Pathol; 2022; 15(4):191-200. PubMed ID: 35535203 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions. Hafez NH; Tahoun NS J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843 [TBL] [Abstract][Full Text] [Related]
8. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. El Hag MI; Ha J; Farag R; El Hag AM; Michael CW Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760 [TBL] [Abstract][Full Text] [Related]
9. Claudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study. Hruaii V; Thirunavukkarasu B; Prabha V; Mathur S; Iyer VK; Nambirajan A; Jain D Diagn Cytopathol; 2024 Jan; 52(1):30-41. PubMed ID: 37837242 [TBL] [Abstract][Full Text] [Related]
10. Additional techniques in serous effusions. Hanselaar AG Anal Cell Pathol; 2002; 24(1):1-4. PubMed ID: 12216539 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and categorization of malignant effusions: A 6-year review from a single academic institution. Lew M; Cantley R; Heider A; Jing X Diagn Cytopathol; 2021 May; 49(5):615-621. PubMed ID: 32275354 [TBL] [Abstract][Full Text] [Related]
13. Refined Diagnosis of Pleural Effusions by Immunocytochemistry of Cell Blocks. Koyi H; Wilander E Anticancer Res; 2023 Feb; 43(2):669-673. PubMed ID: 36697096 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Afify A; Zhou H; Howell L; Paulino AF Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901 [TBL] [Abstract][Full Text] [Related]
15. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Su XY; Li GD; Liu WP; Xie B; Jiang YH Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004 [TBL] [Abstract][Full Text] [Related]
16. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology. Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174 [TBL] [Abstract][Full Text] [Related]
17. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206 [TBL] [Abstract][Full Text] [Related]
18. A panel of markers for identification of malignant and non-malignant cells in culture from effusions. Carneiro FP; Muniz-Junqueira MI; Pittella-Silva F; Carneiro MV; Takano GHS; Vianna LMS; De Andrade LB; De Castro TMML; Peres I; Dos Santos Borges TK; Ferreira VM; Motoyama AB Oncol Rep; 2017 Dec; 38(6):3538-3544. PubMed ID: 29039588 [TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395 [TBL] [Abstract][Full Text] [Related]
20. Quality of cell blocks prepared from residual pleural effusion and bronchial washing samples for immunocytochemistry. Harabajsa S; Milutin L; Breški A; Ražnjević K; Šimić V; Branica BV; Smojver-Ježek S Cytopathology; 2023 May; 34(3):264-270. PubMed ID: 36941745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]